Vaginal Antifungal Label Offering "Clearer Expectation" Of Results Advised
This article was originally published in The Tan Sheet
Executive Summary
FDA's interest in providing labeling information to consumers to help them choose among OTC vaginal antifungals should focus on promoting a clearer understanding of the time to effect for such products, agency advisors suggested Sept. 11.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: